Medium urgency
--
It is the presence of a malignant tumor in the larynx, which is the area of the throat that includes the vocal cords. The larynx is made up of three parts: the glottis (where the vocal cords are located), the supraglottis (above the vocal cords and connected with the pharynx), and the subglottis (below the vocal cords and connected with the trachea). The functions of the larynx are the emission of voice, swallowing and breathing. The tumor will alter any of these functions, depending on its location and its size. Risk factors associated with the development of this cancer: smoking, alcohol consumption, low fruit and vegetable intake, male gender, papillomavirus infection, inhalation of various chemical substances and chronic irritation due to gastric acid reflux. The most common symptoms are hoarseness, sore throat, constant cough, pain when swallowing, difficulty swallowing, earache, difficulty breathing, weight loss, and a lump in the neck. Treatment will depend on the size of the tumor and its extent. In the earliest stages, in which the tumor is localised and smaller, treatment will be surgery or radiation. In the more advanced stages, treatment with radiation therapy and sometimes chemotherapy will be necessary. In the stages where the tumor extends outside the larynx, it will be treated with surgery and then postoperative chemotherapy and radiation therapy. After treatment, rehabilitation may be necessary. After chemotherapy, radiation therapy, and/or surgery, swallowing problems are common and oesophageal dilation or, in severe cases, surgical replacement of the pharynx or gastrostomy feeding tubes may be required. Speech will be more affected in cases where surgery is needed, requiring rehabilitation and speech therapy to regain voice. The 5-year survival rate for laryngeal carcinoma is 61%. However, more than half of patients are diagnosed and treated before the cancer spreads outside the larynx, and in these cases, the 5-year survival rate reaches 76%.
- Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845-852.
- Furusaka T, Matsuda A, Tanaka A, Matsuda H, Ikeda M. Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx. Acta Otolaryngol. 2013;133(6):633-640.
- Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009;115:922-935.
- Mendenhall WM, Werning JW, Pfister DG. Treatment of head and neck cancers. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: 729-780.
- Moyer JS, Wolf GT. Advanced stage cancer of the larynx. Part A: General principles and management. In: Harrison LB, Sessions RB, Hong WK, eds. Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia, pa: Lippincott Williams and Wilkins; 2009: 367-384.
- Romesser PB, Riaz N, Ho AL, Wong RJ, Lee NY. Cancer of the head and neck. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014:1037-1070.
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
- Forastiere AA, Trotti AM. Searching for less toxic larynx preservation: A need for common definitions and metrics. J Natl Cancer Inst. 2009;101:129–131.
- List MA, Stracks J, Colangelo L, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol. 2000;18:877–884.
- Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.
- Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101:142–152.
- Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
- Holsinger FC, Kies MS, Diaz EM, Jr, et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009;27:1976–1982.
- Forastiere AA, Shaha AR. Chemotherapy alone for laryngeal preservation: Is it possible? J Clin Oncol. 2009;27:1933–1934.
© TeckelMedical 2026

